



AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA481)

NICE GUIDANCE ISSUED OCTOBER 2017

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 1712– June 2012

Belatacept (Nulojix®) 250 mg powder for concentrate for solution for infusion

Submission by Bristol-Myers Squibb Pharmaceuticals

Recommendation of AWMSG

Belatacept (Nulojix®) is not recommended as an option for use within NHS Wales, in combination with corticosteroids and a mycophenolic acid, for prophylaxis of graft rejection in adults receiving a renal transplant.

The case for cost effectiveness has not been proven.

Additional note:

- Patients who are currently being treated with belatacept (Nulojix®) for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 430), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation –1712:
Belatacept (Nulojix®) 250 mg powder for concentrate for solution for infusion. June 2012.

